Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

3.65

Margin Of Safety %

Put/Call OI Ratio

0.82

EPS Next Q Diff

0.16

EPS Last/This Y

EPS This/Next Y

1.73

Price

36.82

Target Price

54.76

Analyst Recom

1.31

Performance Q

18.2

Relative Volume

0.66

Beta

1.03

Ticker: ZLAB




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04ZLAB36.40.860.094730
2025-07-07ZLAB35.470.86203.004746
2025-07-08ZLAB34.940.941.004948
2025-07-09ZLAB35.610.940.014949
2025-07-10ZLAB34.070.877.565142
2025-07-11ZLAB32.710.870.525159
2025-07-14ZLAB34.280.860.035210
2025-07-15ZLAB35.170.860.045233
2025-07-16ZLAB35.480.846.505281
2025-07-17ZLAB35.990.850.265311
2025-07-18ZLAB33.580.852.095321
2025-07-21ZLAB34.670.900.145032
2025-07-22ZLAB37.030.860.165186
2025-07-23ZLAB37.370.830.145344
2025-07-24ZLAB37.810.820.415400
2025-07-25ZLAB37.190.821.755410
2025-07-28ZLAB38.690.820.275415
2025-07-29ZLAB40.750.820.405424
2025-07-30ZLAB38.570.801.435492
2025-07-31ZLAB37.820.810.105499
2025-08-01ZLAB36.850.8210.675469
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04ZLAB36.4047.6- -1.46
2025-07-07ZLAB35.4647.6- -1.46
2025-07-08ZLAB34.9447.6- -1.46
2025-07-09ZLAB35.6647.6- -1.46
2025-07-10ZLAB34.0847.6- -1.46
2025-07-11ZLAB32.7347.6- -1.46
2025-07-14ZLAB34.2847.6- -1.46
2025-07-15ZLAB35.1947.6- -1.46
2025-07-16ZLAB35.4847.6- -1.46
2025-07-17ZLAB36.0147.6- -1.46
2025-07-18ZLAB33.5647.6- -1.46
2025-07-21ZLAB34.6447.6- -1.46
2025-07-22ZLAB37.0247.6- -1.46
2025-07-23ZLAB37.3747.6- -1.46
2025-07-24ZLAB37.7749.4- -1.40
2025-07-25ZLAB37.1749.4- -1.40
2025-07-28ZLAB38.7149.4- -1.40
2025-07-29ZLAB40.5149.4- -1.40
2025-07-30ZLAB38.5749.4- -1.40
2025-07-31ZLAB37.8049.4- -1.40
2025-08-01ZLAB36.8249.4- -1.40
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04ZLAB-24.47-4.974.02
2025-07-07ZLAB-24.472.504.02
2025-07-08ZLAB-24.472.504.02
2025-07-09ZLAB-24.472.504.02
2025-07-10ZLAB-24.472.504.02
2025-07-11ZLAB-24.472.503.71
2025-07-14ZLAB-24.472.733.71
2025-07-15ZLAB-24.472.733.71
2025-07-16ZLAB-24.472.733.71
2025-07-17ZLAB-24.472.733.71
2025-07-18ZLAB-24.472.733.71
2025-07-21ZLAB-24.472.813.71
2025-07-22ZLAB-24.472.813.71
2025-07-23ZLAB-24.472.813.71
2025-07-24ZLAB-24.472.813.71
2025-07-25ZLAB-24.472.813.65
2025-07-28ZLAB-24.47-2.033.65
2025-07-29ZLAB-24.47-2.033.65
2025-07-30ZLAB-24.47-2.033.65
2025-07-31ZLAB-24.47-2.033.65
2025-08-01ZLAB-24.47-2.033.65
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.45

Avg. EPS Est. Current Quarter

-0.42

Avg. EPS Est. Next Quarter

-0.29

Insider Transactions

-24.47

Institutional Transactions

-2.03

Beta

1.03

Average Sales Estimate Current Quarter

126

Average Sales Estimate Next Quarter

153

Fair Value

Quality Score

Growth Score

22

Sentiment Score

87

Actual DrawDown %

81

Max Drawdown 5-Year %

-92.8

Target Price

54.76

P/E

Forward P/E

56.99

PEG

P/S

9.74

P/B

4.92

P/Free Cash Flow

EPS

-2.5

Average EPS Est. Cur. Y​

-1.4

EPS Next Y. (Est.)

0.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-60.24

Relative Volume

0.66

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

Zai Lab Limited
Sector: Healthcare
Industry: Biotechnology
Employees: 1869
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
stock quote shares ZLAB – Zai Lab Limited Stock Price stock today
news today ZLAB – Zai Lab Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch ZLAB – Zai Lab Limited yahoo finance google finance
stock history ZLAB – Zai Lab Limited invest stock market
stock prices ZLAB premarket after hours
ticker ZLAB fair value insiders trading